Charles Ryan biography
Dr. Charles Ryan has been appointed Chief Executive Officer, Director of the Company effective February 15, 2018. Dr. Ryan is currently President and Chief Executive Officer of Orthobond Corporation where he is responsible for all aspects of the company’s daily operations and works closely with the Board of Directors developing the short and long term strategic plans for the company. Dr. Ryan has negotiated several partnership, financing and licensing agreements. After leaving Forest Laboratories and prior to joining Orthobond, Dr. Ryan served as Vice President, General Counsel for Cold Spring Harbor Laboratory. In this role at Cold Spring, he provided guidance on business, legal and public policy issues, including licensing, patenting, partnerships, alliances, compliance and regulatory matters. Dr. Ryan currently serves on the Board of two public companies, Applied DNA Sciences, Inc. and BioRestorative Therapies, Inc. as well as Orthobond, Inc. He also serves on the Board of Trustees of The College of Wooster. He holds a BA in Chemistry from The College of Wooster, a PhD in Oral Biology and Pathology from Stony Brook University and a JD from Western New England University.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
How old is Charles Ryan?
Charles Ryan is 51, he's been the Chief Executive Officer und Director of NextTrip since 2018. There are 3 older and 1 younger executives at NextTrip. The oldest executive at NextTrip Inc. is William Singer, 74, who is the Vice Chairman of the Board.
What's Charles Ryan's mailing address?
Charles's mailing address filed with the SEC is 50 Health Sciences Drive, Stony Brook, NY 11790, USA.
Insiders trading at NextTrip
Over the last 10 years, insiders at NextTrip have traded over $2,644 worth of NextTrip stock and bought 245,000 units worth $210,900 . The most active insiders traders include Bruce Bernstein, Ivan P. Gergel und Andrew D Perlman. On average, NextTrip executives and independent directors trade stock every 180 days with the average trade being worth of $69,913. The most recent stock trade was executed by Jonathan Schechter on 30 October 2020, trading 25,000 units of NTRP stock currently worth $24,500.
What does NextTrip do?
sigma labs, inc., develops and engineers advanced, in-process, non-destructive quality inspection systems for commercial firms worldwide seeking productive solutions for metal-based additive manufacturing or 3d printing, and other advanced manufacturing technologies. sigma labs is pioneering the commercialization of in-process metallurgical and geometric quality assurance monitoring technology. printrite3d® with its software modules inspect™, contour™ and analytics™ is the industry's first, commercially available, platform independent, third party in-process quality monitoring system for metal additive manufacturing. it is available as a fully embedded oem installation or a stand-alone connection to your existing machines. additionally, sigma labs conducts contract metal 3d printing in materials inconnel718, 316 stainless, titanium, aluminum and ms1 tool steel. for more information please visit www.sigmalabsinc.com. for inquiries contact: sales@sigmalabsinc.com follow sigma labs on twi
What does NextTrip's logo look like?
NextTrip executives and stock owners
NextTrip executives and other stock owners filed with the SEC include:
-
Robert Weinstein,
Chief Financial Officer, Executive Vice President -
Jonathan Schechter,
Director -
Kenneth Gorelick,
Director -
Ivan Gergel,
Director -
Bruce Bernstein,
Director -
Paula Trzepacz,
Executive Vice President and Chief Medical Officer -
William Singer,
Vice Chairman of the Board -
Charles Ryan,
Chief Executive Officer, Director -
Daniel Alkon,
President, Chief Scientific Officer -
Joshua Silverman,
Chairman of the Board -
Shana Phares,
Director -
George Perry,
Director -
Michael Ciraolo,
COO and General Counsel -
Susanne Wilke,
Director -
James Gottlieb,
Director -
Andrew D Perlman,
Director -
Warren W Wasiewski,
-
Paul E. Freiman,
See Remarks -
Charles S Ramat,
President and CEO -
Larry Douglas Altstiel,
Director -
Jay M Haft,
Director -
John H Abeles,
10% owner -
David Crockford,